华夏创新医药龙头混合C(012982)利润分配表
|
2024-12-31 |
2024-06-30 |
2023-12-31 |
2023-06-30 |
收入 |
-26,494,020.32 |
-29,037,210.47 |
-27,191,406.73 |
-23,426,356.49 |
利息合计 |
96,841.42 |
50,845.08 |
145,235.93 |
65,215.11 |
其中:存款利息收入 |
96,841.42 |
50,845.08 |
145,235.93 |
65,215.11 |
债券利息收入 |
- |
- |
- |
- |
资产支持证券利息收入 |
- |
- |
- |
- |
买入返售金融资产收入 |
- |
- |
- |
- |
投资收益合计 |
-21,407,795.29 |
-20,567,529.36 |
-24,386,031.28 |
-13,128,532.10 |
其中:股票投资收益 |
-22,700,593.38 |
-21,589,711.29 |
-25,774,098.13 |
-14,435,032.29 |
基金投资收益 |
- |
- |
- |
- |
债券投资收益 |
18,168.39 |
- |
43,931.05 |
530.90 |
资产支持证券投资收益 |
- |
- |
- |
- |
衍生工具收益 |
- |
- |
- |
- |
股利收益 |
1,274,629.70 |
1,022,181.93 |
1,344,135.80 |
1,305,969.29 |
基金分红收益收益 |
- |
- |
- |
- |
公允价值变动收益 |
-5,315,356.49 |
-8,596,815.29 |
-3,122,818.35 |
-10,468,526.92 |
其他收入 |
132,290.04 |
76,289.10 |
172,206.97 |
105,487.42 |
费用 |
3,065,174.26 |
1,611,728.12 |
4,184,439.07 |
2,270,328.54 |
管理人报酬 |
2,021,090.20 |
1,052,071.51 |
2,851,252.03 |
1,597,343.38 |
基金托管费 |
336,848.41 |
175,345.27 |
419,398.89 |
212,979.06 |
销售服务费 |
559,153.00 |
297,070.92 |
739,051.08 |
373,569.78 |
交易费用 |
- |
- |
- |
- |
利息支出 |
- |
- |
- |
- |
其中:卖出回购金融资产支出 |
- |
- |
- |
- |
其他费用 |
148,082.45 |
87,240.42 |
174,736.95 |
86,436.27 |
利润总额 |
-29,559,194.58 |
-30,648,938.59 |
-31,375,845.80 |
-25,696,685.03 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年